ALPHAMAB-B (09966) repurchased 60,000 shares for HK$486,500 on September 22.
ALPHAMAB-B (09966) announced that on September 22, 2026, the company repurchased 60,000 shares for HK$486,500, at a repurchase price of HK$8.095 to HK$8.12 per share.
ALPHAMAB-B (09966) announced that on September 22, 2026, the company repurchased 60,000 shares for HK$486,500, at a repurchase price of HK$8.095 to HK$8.12 per share.
Related Articles
AI infrastructure supplier Accelevation (ACCV.US) races toward U.S. IPO, valued at up to $5.37 billion.
SF INTRA-CITY (09699) repurchased 896,000 shares for HK$7.9905 million on September 22.
Changchun High-Tech Industry (000661.SZ): Clinical trial application for the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination product has been accepted.
AI infrastructure supplier Accelevation (ACCV.US) races toward U.S. IPO, valued at up to $5.37 billion.
SF INTRA-CITY (09699) repurchased 896,000 shares for HK$7.9905 million on September 22.
Changchun High-Tech Industry (000661.SZ): Clinical trial application for the recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination product has been accepted.
